ORMP (oramed.com) Future Price to Earnings

Official company branding of Oramed Pharmaceuticals Inc. (ORMP)

This daily chart from the GURU.Markets service illustrates the future P/E ratio for Oramed Pharmaceuticals (ORMP), where the 0.00 mark captures this metric. The company is currently reviewing its assets following unsuccessful trials while maintaining margins at previous levels. The innovative POD technology enables the creation of oral insulin tablets by protecting the protein in the stomach. However, a capital shortage and the risk of failure for key developments pose serious threats to the business's survival.

Oramed Pharmaceuticals - ORMP Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Oramed Pharma (ORMP)

- current price and projected stock value:
Stock Quotes Oramed Pharmaceuticals|ORMP - Fair Value Consensus
- business market valuation indicators:
Market Value Oramed|ORMP - Total Enterprise Value
- balance sheet equity data:
Accounting Value per Share Oramed Pharmaceuticals|ORMP - Total Net Assets|Market Capitalization to Book Value Ratio oramed.com|ORMP - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital Oramed Pharmaceuticals|ORMP - Long-Term Liabilities to Capital|Short-Term Debt to Equity Oramed Pharmaceuticals|ORMP - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Oramed|ORMP - Long-Term Debt|Company Short-Term Debt Oramed Pharmaceuticals|Quick Ratio oramed.com
- financial results and valuation multiples details:
ORMP - Net Profit|Expected Profit Oramed Pharmaceuticals|ORMP - Price to Earnings Ratio|Forward P/E Multiple Oramed Pharmaceuticals|ORMP - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Oramed|ORMP - Operating profit before amortization|Net earnings per share for the last 12 months Oramed Pharmaceuticals|ORMP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months oramed.com|ORMP - Earnings per share trend in current year|Earnings growth forecast for next year Oramed Pharmaceuticals
Fundamental valuation:ORMP Oramed Pharmaceuticals Inc.
Brand item of Oramed Pharmaceuticals

Fundamental asset screening requires analyzing the ratio of market capitalization to expected earnings, which allows for an assessment of whether a security is overbought or undervalued. The trend of the forward P/E for Oramed Pharmaceuticals (ORMP) reflects analyst consensus forecasts, where a decreasing multiple enhances the resilience of ORMP quotes against market shocks amid the development of a revolutionary oral insulin delivery platform.

Competitors of Oramed Pharmaceuticals (ORMP)

Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Future Price to Earnings Amphastar Pharmaceuticals, Inc. AMPH|Pacira Pharmaceuticals (PCRX) - Projected Price to Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Corp)|AQST: Forward P/E Multiple|scPharmaceuticals (SCPH) - Forward P/E Multiple|Future Price to Earnings Tectonic Therapeutic Inc.|Projected Price to Earnings Tonix Pharma (TNXP)|Forward P/E Multiple SXTC|EPRX - Projected Price to Earnings Ratio|Forward P/E Multiple BHST (BioHarvest Sciences)|EXOZ: Price to Future Earnings Ratio|ENTX: Projected Price to Earnings|Future Price to Earnings Multiple HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma Inc (ABVC) - Future Price to Earnings|Price to Expected Earnings Ratio CPIX (Cumberland Corp)|QNTM (Quantum BioPharma Ltd) - Forward P/E Multiple|FGEN: Future Price to Earnings Multiple|Forward P/E Multiple TELO|Forward P/E Multiple ranitherapeutics.com (RANI)|Future Price to Earnings Synergy CHC SNYR|Future Price to Earnings Multiple RLYB|LEXX - Future Price to Earnings|pulmatrix.com (PULM) - Projected Price to Earnings|PTHL: Forward P/E Multiple|Aptorum Group (APM) - Forward P/E Multiple|LYRA (Lyra Therapeutics, Inc) - Forward P/E Multiple|Projected Price to Earnings Impact BioMedical, Inc. (IBO)|Forward P/E Multiple TNFA|YCBD - Projected Price to Earnings Ratio|PainReform - Projected Price to Earnings|Forward P/E Multiple Altamira Therapeutics Ltd CYTO|LIPO: Projected Price to Earnings|OptiNose Corp - Market Cap to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharmaceuticals, Inc.) - Forward P/E Multiple|Projected Price to Earnings Qilian International Holding Group (QLI)|Forward P/E Multiple SLRN|Forward P/E Multiple TFF Pharmaceuticals, Inc (TFFP)